메뉴 건너뛰기




Volumn 26, Issue 6, 2005, Pages 485-500

Rituximab: A original biotherapy in auto-immune disorders;Le rituximab: Une biothérapie originale dans les maladies auto-immunes

Author keywords

Antilymphocytes; Auto immun disorders; CD 20; Lymphocytes B; Rituximab

Indexed keywords

RITUXIMAB;

EID: 20344400358     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.revmed.2004.12.013     Document Type: Short Survey
Times cited : (19)

References (127)
  • 1
    • 0037388277 scopus 로고    scopus 로고
    • Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders
    • I. Matsumoto, D.M. Lee, R. Goldbach-Mansky, T. Sumida, C.A. Hitchon, and P.H. Schur Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders Arthritis Rheum. 48 2003 944 954
    • (2003) Arthritis Rheum. , vol.48 , pp. 944-954
    • Matsumoto, I.1    Lee, D.M.2    Goldbach-Mansky, R.3    Sumida, T.4    Hitchon, C.A.5    Schur, P.H.6
  • 2
    • 0037732689 scopus 로고    scopus 로고
    • The role of B cells in rheumatoid arthritis: Mechanisms and therapeutic targets
    • T. Dorner, and G. Burmester The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets Curr. Opin. Rheumatol. 15 2003 246 252
    • (2003) Curr. Opin. Rheumatol. , vol.15 , pp. 246-252
    • Dorner, T.1    Burmester, G.2
  • 3
    • 10744224617 scopus 로고    scopus 로고
    • B Lymphocyte stimulator overexpression in patients with systemic lupus erythematous
    • W. Stohl, S. Metsyas, S.M. Tan, G.S. Cheema, B. Oamar, and D. Xu B Lymphocyte stimulator overexpression in patients with systemic lupus erythematous Arthritis Rheum. 48 2003 3475 3486
    • (2003) Arthritis Rheum. , vol.48 , pp. 3475-3486
    • Stohl, W.1    Metsyas, S.2    Tan, S.M.3    Cheema, G.S.4    Oamar, B.5    Xu, D.6
  • 4
    • 0036732753 scopus 로고    scopus 로고
    • Dendritic cells CD40-independent immunoglobulin class switching through BlyS and APRIL
    • M.B. Litinskiy, B. Nardelli, D.M. Hilbert, B. He, A. Schaffer, and P. Casali Dendritic cells CD40-independent immunoglobulin class switching through BlyS and APRIL Nat. Immunol. 3 2002 822 829
    • (2002) Nat. Immunol. , vol.3 , pp. 822-829
    • Litinskiy, M.B.1    Nardelli, B.2    Hilbert, D.M.3    He, B.4    Schaffer, A.5    Casali, P.6
  • 5
    • 9144244817 scopus 로고    scopus 로고
    • Cutting Edge: BAFF Regulates CD21/35 and CD23 Expression Independent of Its B Cell Survival Function
    • L. Gorelik, A.H. Cutler, G. Thill, S.D. Miklasz, D.E. Shea, and C. Ambrose Cutting Edge: BAFF Regulates CD21/35 and CD23 Expression Independent of Its B Cell Survival Function J. Immunol 172 2004 762 766
    • (2004) J. Immunol , vol.172 , pp. 762-766
    • Gorelik, L.1    Cutler, A.H.2    Thill, G.3    Miklasz, S.D.4    Shea, D.E.5    Ambrose, C.6
  • 6
    • 0242495115 scopus 로고    scopus 로고
    • Generation and characterization of lymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
    • K.P. Baker, B.M. Edwards, S.H. Main, G.H. Choi, R.E. Wager, and W.G. Halpern Generation and characterization of lymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator Arthritis Rheum. 48 2003 3253 3268
    • (2003) Arthritis Rheum. , vol.48 , pp. 3253-3268
    • Baker, K.P.1    Edwards, B.M.2    Main, S.H.3    Choi, G.H.4    Wager, R.E.5    Halpern, W.G.6
  • 7
    • 0033577903 scopus 로고    scopus 로고
    • A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus
    • O.T. Chan, L.G. Hannum, A.M. Haberman, M.P. Madaio, and M.J. Shlomchik A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus J. Exp. Med. 189 1999 1639 1648
    • (1999) J. Exp. Med. , vol.189 , pp. 1639-1648
    • Chan, O.T.1    Hannum, L.G.2    Haberman, A.M.3    Madaio, M.P.4    Shlomchik, M.J.5
  • 9
    • 0037450740 scopus 로고    scopus 로고
    • Prevention of arthritis by interleukin 10-producing B cells
    • C. Mauri, D. Gray, N. Mushtaq, and M. Londei Prevention of arthritis by interleukin 10-producing B cells J. Exp. Med. 197 2003 489 501
    • (2003) J. Exp. Med. , vol.197 , pp. 489-501
    • Mauri, C.1    Gray, D.2    Mushtaq, N.3    Londei, M.4
  • 10
    • 0035677256 scopus 로고    scopus 로고
    • Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment
    • J. Bienvenu, R. Chvetzoff, G. Salles, C. Balter, H. Tilly, and R. Herbrecht Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment Hematol. J. 2 2001 378 384
    • (2001) Hematol. J. , vol.2 , pp. 378-384
    • Bienvenu, J.1    Chvetzoff, R.2    Salles, G.3    Balter, C.4    Tilly, H.5    Herbrecht, R.6
  • 12
    • 0034999619 scopus 로고    scopus 로고
    • Tumor Cell Expression of CD59 Is Associated with Resistance to CD20 Serotherapy in Patients with B-Cell Malignancies
    • S.P. Treon, C. Mitsiades, N. Mitsiades, G. Young, D. Doss, and R. Schlossman Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies J. Immunother. 24 2001 263 271
    • (2001) J. Immunother. , vol.24 , pp. 263-271
    • Treon, S.P.1    Mitsiades, C.2    Mitsiades, N.3    Young, G.4    Doss, D.5    Schlossman, R.6
  • 13
    • 0035122440 scopus 로고    scopus 로고
    • Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
    • G.V. Gonzalez-Stawinski, P.B. Yu, S.D. Love, W. Parker, and R.D. Davis Jr. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) Clin. Immunol. 98 2001 175 179
    • (2001) Clin. Immunol. , vol.98 , pp. 175-179
    • Gonzalez-Stawinski, G.V.1    Yu, P.B.2    Love, S.D.3    Parker, W.4    Davis Jr., R.D.5
  • 14
    • 0037563999 scopus 로고    scopus 로고
    • No clinical evidence for CD4+ cell depletion caused by rituximab
    • M.W. Saville, M.C. Benyunes, and P.S. Multani No clinical evidence for CD4+ cell depletion caused by rituximab Blood 102 2003 408 409 408; author reply
    • (2003) Blood , vol.102 , pp. 408-409
    • Saville, M.W.1    Benyunes, M.C.2    Multani, P.S.3
  • 16
    • 0034104375 scopus 로고    scopus 로고
    • Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
    • D. Shan, J.A. Ledbetter, and O.W. Press Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells Cancer Immunol. Immunother. 48 2000 673 683
    • (2000) Cancer Immunol. Immunother. , vol.48 , pp. 673-683
    • Shan, D.1    Ledbetter, J.A.2    Press, O.W.3
  • 17
    • 0033855194 scopus 로고    scopus 로고
    • Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis
    • J.K. Hofmeister, D. Cooney, and K.M. Coggeshall Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis Blood Cells Mol. Dis. 26 2000 133 143
    • (2000) Blood Cells Mol. Dis. , vol.26 , pp. 133-143
    • Hofmeister, J.K.1    Cooney, D.2    Coggeshall, K.M.3
  • 18
    • 0037082469 scopus 로고    scopus 로고
    • The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism
    • I.M. Pedersen, A.M. Buhl, P. Klausen, C.H. Geisler, and J. Jurlander The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase- dependent mechanism Blood 99 2002 1314 1319
    • (2002) Blood , vol.99 , pp. 1314-1319
    • Pedersen, I.M.1    Buhl, A.M.2    Klausen, P.3    Geisler, C.H.4    Jurlander, J.5
  • 19
    • 0037306946 scopus 로고    scopus 로고
    • Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
    • M.S. Cragg, S.M. Morgan, H.T. Chan, B.P. Morgan, A.V. Filatov, and P.W. Johnson Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts Blood 101 2003 1045 1052
    • (2003) Blood , vol.101 , pp. 1045-1052
    • Cragg, M.S.1    Morgan, S.M.2    Chan, H.T.3    Morgan, B.P.4    Filatov, A.V.5    Johnson, P.W.6
  • 20
    • 0037439821 scopus 로고    scopus 로고
    • Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells
    • I. Semac, C. Palomba, K. Kulangara, N. Klages, G. Van Echten-Deckert, and B. Borisch Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells Cancer Res. 63 2003 534 540
    • (2003) Cancer Res. , vol.63 , pp. 534-540
    • Semac, I.1    Palomba, C.2    Kulangara, K.3    Klages, N.4    Van Echten-Deckert, G.5    Borisch, B.6
  • 21
    • 0242492546 scopus 로고    scopus 로고
    • Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
    • I. Jilani, S. O'Brien, T. Manshuri, D.A. Thomas, V.A. Thomazy, and M. Imam Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia Blood 102 2003 3514 3520
    • (2003) Blood , vol.102 , pp. 3514-3520
    • Jilani, I.1    O'Brien, S.2    Manshuri, T.3    Thomas, D.A.4    Thomazy, V.A.5    Imam, M.6
  • 22
    • 1342282157 scopus 로고    scopus 로고
    • Rituximab infusion promotes rapid complement depletion and acute CD 20 Loss in chronic lymphocytic leukemia
    • A.D. Kennedy, P.V. Beum, M.D. Solga, D.J. DiLillo, M.A. Lindorfer, and C.E. Hess Rituximab infusion promotes rapid complement depletion and acute CD 20 Loss in chronic lymphocytic leukemia J. Immunol. 172 2004 3280 3288
    • (2004) J. Immunol. , vol.172 , pp. 3280-3288
    • Kennedy, A.D.1    Beum, P.V.2    Solga, M.D.3    Dilillo, D.J.4    Lindorfer, M.A.5    Hess, C.E.6
  • 24
    • 0042236345 scopus 로고    scopus 로고
    • Mechanism of action and resistance to monoclonal antibody therapy
    • N. Villamor, E. Montserrat, and D. Colomer Mechanism of action and resistance to monoclonal antibody therapy Semin. Oncol. 30 2003 424 433
    • (2003) Semin. Oncol. , vol.30 , pp. 424-433
    • Villamor, N.1    Montserrat, E.2    Colomer, D.3
  • 25
    • 0032030699 scopus 로고    scopus 로고
    • Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
    • D. Shan, J.A. Ledbetter, and O.W. Press Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91 1998 1644 1652
    • (1998) Blood , vol.91 , pp. 1644-1652
    • Shan, D.1    Ledbetter, J.A.2    Press, O.W.3
  • 26
    • 0034777814 scopus 로고    scopus 로고
    • CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
    • N. Selenko, O. Maidic, S. Draxier, A. Berer, U. Jager, and W. Knapp CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells Leukemia 15 2001 1619 1626
    • (2001) Leukemia , vol.15 , pp. 1619-1626
    • Selenko, N.1    Maidic, O.2    Draxier, S.3    Berer, A.4    Jager, U.5    Knapp, W.6
  • 27
    • 0036408912 scopus 로고    scopus 로고
    • CD20-mediated apoptosis: Signalling through lipid rafts
    • J.P. Deans, H. Li, and M.J. Polyak CD20-mediated apoptosis: signalling through lipid rafts Immunology 107 2002 176 182
    • (2002) Immunology , vol.107 , pp. 176-182
    • Deans, J.P.1    Li, H.2    Polyak, M.J.3
  • 28
    • 0036464611 scopus 로고    scopus 로고
    • The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction
    • J.C. Byrd, S. Kitada, I.W. Flinn, J.L. Aron, M. Pearson, and D. Lucas The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction Blood 99 2002 1038 1043
    • (2002) Blood , vol.99 , pp. 1038-1043
    • Byrd, J.C.1    Kitada, S.2    Flinn, I.W.3    Aron, J.L.4    Pearson, M.5    Lucas, D.6
  • 29
    • 0036307780 scopus 로고    scopus 로고
    • Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma
    • S. Alas, C.P. Ng, and B. Bonavida Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma Clin. Cancer Res. 2002 836 845
    • (2002) Clin. Cancer Res. , pp. 836-845
    • Alas, S.1    Ng, C.P.2    Bonavida, B.3
  • 30
    • 0038518572 scopus 로고    scopus 로고
    • Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance
    • R. Bannerji, S. Kitada, I.W. Flinn, M. Pearson, D. Young, and J.C. Reed Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance J. Clin. Oncol. 21 2003 1466 1471
    • (2003) J. Clin. Oncol. , vol.21 , pp. 1466-1471
    • Bannerji, R.1    Kitada, S.2    Flinn, I.W.3    Pearson, M.4    Young, D.5    Reed, J.C.6
  • 31
    • 0036179899 scopus 로고    scopus 로고
    • Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines
    • P.M. Cardarelli, M. Quinn, D. Buckman, Y. Fang, D. Colcher, and D.J. King Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines Cancer Immunol. Immunother. 51 2002 15 24
    • (2002) Cancer Immunol. Immunother. , vol.51 , pp. 15-24
    • Cardarelli, P.M.1    Quinn, M.2    Buckman, D.3    Fang, Y.4    Colcher, D.5    King, D.J.6
  • 32
    • 0035469885 scopus 로고    scopus 로고
    • Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
    • W.K. Weng, and R. Levy Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood 98 2001 1352 1357
    • (2001) Blood , vol.98 , pp. 1352-1357
    • Weng, W.K.1    Levy, R.2
  • 33
    • 0035760902 scopus 로고    scopus 로고
    • CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59
    • J. Golay, M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, and T. Barbui CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood 98 2001 3383 3389
    • (2001) Blood , vol.98 , pp. 3383-3389
    • Golay, J.1    Lazzari, M.2    Facchinetti, V.3    Bernasconi, S.4    Borleri, G.5    Barbui, T.6
  • 34
    • 0035525769 scopus 로고    scopus 로고
    • Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
    • B. Bellosillo, N. Villamor, A. Lopez-Guillermo, S. Marce, J. Esteve, and E. Campo Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species Blood 98 2001 2771 2777
    • (2001) Blood , vol.98 , pp. 2771-2777
    • Bellosillo, B.1    Villamor, N.2    Lopez-Guillermo, A.3    Marce, S.4    Esteve, J.5    Campo, E.6
  • 36
    • 0037306893 scopus 로고    scopus 로고
    • In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
    • O. Manches, G. Lui, L. Chaperot, R. Gressin, J.P. Molens, and M.C. Jacob In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas Blood 101 2003 949 954
    • (2003) Blood , vol.101 , pp. 949-954
    • Manches, O.1    Lui, G.2    Chaperot, L.3    Gressin, R.4    Molens, J.P.5    Jacob, M.C.6
  • 37
    • 0034660092 scopus 로고    scopus 로고
    • Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    • J. Golay, L. Zaffaroni, T. Vaccari, M. Lazzari, G.M. Borleri, and S. Bernasconi Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 95 2000 3900 3908
    • (2000) Blood , vol.95 , pp. 3900-3908
    • Golay, J.1    Zaffaroni, L.2    Vaccari, T.3    Lazzari, M.4    Borleri, G.M.5    Bernasconi, S.6
  • 38
    • 0034076307 scopus 로고    scopus 로고
    • Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
    • R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat. Med. 6 2000 443 446
    • (2000) Nat. Med. , vol.6 , pp. 443-446
    • Clynes, R.A.1    Towers, T.L.2    Presta, L.G.3    Ravetch, J.V.4
  • 39
    • 0036464719 scopus 로고    scopus 로고
    • Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    • G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, and P. Colombat Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 2002 754 758
    • (2002) Blood , vol.99 , pp. 754-758
    • Cartron, G.1    Dacheux, L.2    Salles, G.3    Solal-Celigny, P.4    Bardos, P.5    Colombat, P.6
  • 40
    • 0642373290 scopus 로고    scopus 로고
    • Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
    • W.K. Weng, and R. Levy Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J. Clin. Oncol. 21 2003 3940 3947
    • (2003) J. Clin. Oncol. , vol.21 , pp. 3940-3947
    • Weng, W.K.1    Levy, R.2
  • 41
    • 0842264005 scopus 로고    scopus 로고
    • Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
    • S.S. Farag, I.W. Flinn, R. Modali, T.A. Lehman, D. Young, and J.C. Byrd Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia Blood 103 2004 1472 1474
    • (2004) Blood , vol.103 , pp. 1472-1474
    • Farag, S.S.1    Flinn, I.W.2    Modali, R.3    Lehman, T.A.4    Young, D.5    Byrd, J.C.6
  • 42
    • 0037289807 scopus 로고    scopus 로고
    • The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
    • J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, I. Sanz, and J. Rosenblatt The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus Arthritis Rheum. 48 2003 455 459
    • (2003) Arthritis Rheum. , vol.48 , pp. 455-459
    • Anolik, J.H.1    Campbell, D.2    Felgar, R.E.3    Young, F.4    Sanz, I.5    Rosenblatt, J.6
  • 43
    • 0034091481 scopus 로고    scopus 로고
    • Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
    • A. Harjunpaa, S. Junnikkala, and S. Meri rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms Scand. J. Immunol. 51 2000 634 641
    • (2000) Scand. J. Immunol. , vol.51 , pp. 634-641
    • Harjunpaa, A.1    Junnikkala, S.2    Meri, S.3
  • 44
    • 0042346042 scopus 로고    scopus 로고
    • Complement activation determines the therapeutic activity of rituximab in vivo
    • N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, and E. Scanziani Complement activation determines the therapeutic activity of rituximab in vivo J. Immunol. 171 2003 1581 1587
    • (2003) J. Immunol. , vol.171 , pp. 1581-1587
    • Di Gaetano, N.1    Cittera, E.2    Nota, R.3    Vecchi, A.4    Grieco, V.5    Scanziani, E.6
  • 45
    • 0037306990 scopus 로고    scopus 로고
    • An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab
    • A.D. Kennedy, M.D. Solga, T.A. Schuman, A.W. Chi, M.A. Lindorfer, and W.M. Sutherland An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab Blood 101 2003 1071 1079
    • (2003) Blood , vol.101 , pp. 1071-1079
    • Kennedy, A.D.1    Solga, M.D.2    Schuman, T.A.3    Chi, A.W.4    Lindorfer, M.A.5    Sutherland, W.M.6
  • 46
    • 0642312825 scopus 로고    scopus 로고
    • Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance
    • M.R. Smith Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene 22 2003 7359 7368
    • (2003) Oncogene , vol.22 , pp. 7359-7368
    • Smith, M.R.1
  • 48
    • 0034861959 scopus 로고    scopus 로고
    • Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma
    • A. Harjunpaa, T. Wiklund, J. Collan, R. Janes, J. Rosenberg, and D. Lee Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma Leuk. Lymphoma 42 2001 731 738
    • (2001) Leuk. Lymphoma , vol.42 , pp. 731-738
    • Harjunpaa, A.1    Wiklund, T.2    Collan, J.3    Janes, R.4    Rosenberg, J.5    Lee, D.6
  • 49
    • 0033855660 scopus 로고    scopus 로고
    • Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
    • T.A. Davis, A.J. Grillo-Lopez, C.A. White, P. McLaughlin, M.S. Czuczman, and B.K. Link Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment J. Clin. Oncol. 18 2000 3135 3143
    • (2000) J. Clin. Oncol. , vol.18 , pp. 3135-3143
    • Davis, T.A.1    Grillo-Lopez, A.J.2    White, C.A.3    McLaughlin, P.4    Czuczman, M.S.5    Link, B.K.6
  • 51
    • 0036441027 scopus 로고    scopus 로고
    • Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review
    • G.A. Kennedy, S.K. Tey, R. Cobcroft, P. Marlton, G. Cull, and K. Grimmett Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review Br. J. Haematol. 119 2002 412 416
    • (2002) Br. J. Haematol. , vol.119 , pp. 412-416
    • Kennedy, G.A.1    Tey, S.K.2    Cobcroft, R.3    Marlton, P.4    Cull, G.5    Grimmett, K.6
  • 52
    • 0034786134 scopus 로고    scopus 로고
    • Loss of CD 20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): A retrospective cohort analysis
    • J.M. Foran, A.J. Norton, I.N. Micallef, D.C. Taussig, J.A. Amess, and A.Z. Rohatiner Loss of CD 20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis Br. J. Haematol. 114 2001 881 883
    • (2001) Br. J. Haematol. , vol.114 , pp. 881-883
    • Foran, J.M.1    Norton, A.J.2    Micallef, I.N.3    Taussig, D.C.4    Amess, J.A.5    Rohatiner, A.Z.6
  • 53
    • 0038446696 scopus 로고    scopus 로고
    • Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance
    • T. Manshouri, K.A. Do, X. Wang, F.J. Giles, S.M. O'Brien, and H. Saffer Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance Blood 101 2003 2507 2513
    • (2003) Blood , vol.101 , pp. 2507-2513
    • Manshouri, T.1    Do, K.A.2    Wang, X.3    Giles, F.J.4    O'Brien, S.M.5    Saffer, H.6
  • 54
    • 0037105388 scopus 로고    scopus 로고
    • Colocalization of the cell receptor and CD 20 followed by activation-dependent dissocation in distinct lipid rafts
    • R.J. Petrie, and J.P. Deans Colocalization of the cell receptor and CD 20 followed by activation-dependent dissocation in distinct lipid rafts J. Immunol. 15 2002 2886 2891
    • (2002) J. Immunol. , vol.15 , pp. 2886-2891
    • Petrie, R.J.1    Deans, J.P.2
  • 55
    • 0037926797 scopus 로고    scopus 로고
    • Agranulocytosis unresponsive to growth factors following rituximab in vivo purging
    • A.L. Rose, A.M. Forsythe, and D.G. Maloney Agranulocytosis unresponsive to growth factors following rituximab in vivo purging Blood 101 2003 4225 4226
    • (2003) Blood , vol.101 , pp. 4225-4226
    • Rose, A.L.1    Forsythe, A.M.2    Maloney, D.G.3
  • 56
    • 0036264292 scopus 로고    scopus 로고
    • Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor
    • E. Kimby Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor Semin. Oncol. 29 Suppl 6 2002 7 10 [corrected]
    • (2002) Semin. Oncol. , vol.29 , Issue.6 SUPPL. , pp. 7-10
    • Kimby, E.1
  • 57
    • 1842474927 scopus 로고    scopus 로고
    • Rituximab for primary chronic cold agglutinin disease: A prospective study of 37 courses of therapy in 27 patients
    • S. Berentsen, E. Ulvestad, B.T. Gjertsen, H. Hjorth-Hansen, R. Langholm, and H. Knutsen Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients Blood 103 2004 2925 2928
    • (2004) Blood , vol.103 , pp. 2925-2928
    • Berentsen, S.1    Ulvestad, E.2    Gjertsen, B.T.3    Hjorth-Hansen, H.4    Langholm, R.5    Knutsen, H.6
  • 59
    • 1442331704 scopus 로고    scopus 로고
    • Rituximab administration following autologous stem cell transplantion for multiple myeloma is associated with severe IgM deficiently
    • S.H. Lim, Y. Zhang, Z. Wang, R. Varadarajan, P. Periman, and W.V. Esler Rituximab administration following autologous stem cell transplantion for multiple myeloma is associated with severe IgM deficiently Blood 103 2004 1971 1972
    • (2004) Blood , vol.103 , pp. 1971-1972
    • Lim, S.H.1    Zhang, Y.2    Wang, Z.3    Varadarajan, R.4    Periman, P.5    Esler, W.V.6
  • 60
    • 0036235410 scopus 로고    scopus 로고
    • Plasma cells for a lifetime?
    • R.A. Manz, and A. Radbruch Plasma cells for a lifetime? Eur. J. Immunol. 32 2002 923 927
    • (2002) Eur. J. Immunol. , vol.32 , pp. 923-927
    • Manz, R.A.1    Radbruch, A.2
  • 62
    • 0035463152 scopus 로고    scopus 로고
    • Presence of a population of CD20+, CD38- B lymphocytes with defective proliferation responsiveness in the synovial compartment of patients with rheumatoid arthritis
    • C.C. Reparon-Schuijt, W.J. Van Esch, C. Van Kooten, N.P. Ezendam, E.W. Levarht, and F.C. Breedveld Presence of a population of CD20+, CD38- B lymphocytes with defective proliferation responsiveness in the synovial compartment of patients with rheumatoid arthritis Arthritis Rheum. 44 2001 2029 2037
    • (2001) Arthritis Rheum. , vol.44 , pp. 2029-2037
    • Reparon-Schuijt, C.C.1    Van Esch, W.J.2    Van Kooten, C.3    Ezendam, N.P.4    Levarht, E.W.5    Breedveld, F.C.6
  • 63
    • 0037638841 scopus 로고    scopus 로고
    • Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy
    • G.J. Silverman, and S. Weisman Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy Arthritis Rheum. 48 2003 1484 1492
    • (2003) Arthritis Rheum. , vol.48 , pp. 1484-1492
    • Silverman, G.J.1    Weisman, S.2
  • 64
    • 0032697669 scopus 로고    scopus 로고
    • Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma
    • A. Protheroe, J.C. Edwards, A. Simmons, K. Maclennan, and P. Selby Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma Rheumatol. 38 1999 1150 1152
    • (1999) Rheumatol. , vol.38 , pp. 1150-1152
    • Protheroe, A.1    Edwards, J.C.2    Simmons, A.3    MacLennan, K.4    Selby, P.5
  • 65
    • 0035093233 scopus 로고    scopus 로고
    • Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
    • J.C. Edwards, and G. Cambridge Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatol. 40 2001 205 211
    • (2001) Rheumatol. , vol.40 , pp. 205-211
    • Edwards, J.C.1    Cambridge, G.2
  • 66
    • 0036785351 scopus 로고    scopus 로고
    • Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
    • M.J. Leandro, J.C. Edwards, and G. Cambridge Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann. Rheum. Dis. 61 2002 883 888
    • (2002) Ann. Rheum. Dis. , vol.61 , pp. 883-888
    • Leandro, M.J.1    Edwards, J.C.2    Cambridge, G.3
  • 67
    • 0036676817 scopus 로고    scopus 로고
    • Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells
    • S. De Vita, F. Zaja, S. Sacco, A. De Candia, R. Fanin, and G. Ferraccioli Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells Arthritis Rheum. 46 2002 2029 2033
    • (2002) Arthritis Rheum. , vol.46 , pp. 2029-2033
    • De Vita, S.1    Zaja, F.2    Sacco, S.3    De Candia, A.4    Fanin, R.5    Ferraccioli, G.6
  • 68
    • 0142219187 scopus 로고    scopus 로고
    • Successful treatment of infliximab-refractory rheumatoid arthritis with rituximab
    • J.M. Tuscano Successful treatment of infliximab-refractory rheumatoid arthritis with rituximab Arthritis Rheum 46 2002 3420 LB11
    • (2002) Arthritis Rheum , vol.46 , pp. 3420
    • Tuscano, J.M.1
  • 69
    • 0142218537 scopus 로고    scopus 로고
    • B cell therapy for rheumatoid arthritis: The rituximab (anti-CD20) experience
    • T. Shaw, J. Quan, and M.C. Totoritis B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience Ann. Rheum. Dis. 62 2003 ii55 ii59
    • (2003) Ann. Rheum. Dis. , vol.62
    • Shaw, T.1    Quan, J.2    Totoritis, M.C.3
  • 71
    • 0042173008 scopus 로고    scopus 로고
    • SLE - Rituximab in lupus
    • R. Eisenberg SLE - Rituximab in lupus Arthritis Res. Ther. 5 2003 157 159
    • (2003) Arthritis Res. Ther. , vol.5 , pp. 157-159
    • Eisenberg, R.1
  • 72
    • 0000731503 scopus 로고    scopus 로고
    • B lymphocyte depletion as a novel treatment for systemic lupus erythematous: Phase I/II trial of rituximab (Rituxan) in SLE
    • J.H. Anolik, D. Campbell, C. Ritchlin, M. Holyst, S. Rosenfeld, and C. Varnis B lymphocyte depletion as a novel treatment for systemic lupus erythematous: phase I/II trial of rituximab (Rituxan) in SLE Arthritis Rheum. 44 Suppl 9 2001 387
    • (2001) Arthritis Rheum. , vol.44 , Issue.9 SUPPL. , pp. 387
    • Anolik, J.H.1    Campbell, D.2    Ritchlin, C.3    Holyst, M.4    Rosenfeld, S.5    Varnis, C.6
  • 74
    • 0142087478 scopus 로고    scopus 로고
    • Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy
    • R. Weide, J. Heymanns, A. Pandorf, and H. Koppler Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy Lupus 12 2003 779 782
    • (2003) Lupus , vol.12 , pp. 779-782
    • Weide, R.1    Heymanns, J.2    Pandorf, A.3    Koppler, H.4
  • 75
    • 0142119138 scopus 로고    scopus 로고
    • Remission of refractory lupus nephritis with a protocol including rituximab
    • G.P. Fra, G.C. Avanzi, and E. Bartoli Remission of refractory lupus nephritis with a protocol including rituximab Lupus 12 2003 783 787
    • (2003) Lupus , vol.12 , pp. 783-787
    • Fra, G.P.1    Avanzi, G.C.2    Bartoli, E.3
  • 76
    • 0036180868 scopus 로고    scopus 로고
    • Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus
    • S. Perrotta, F. Locatelli, A. La Manna, L. Cennamo, P. De Stefano, and B. Nobili Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus Br. J. Haematol. 116 2002 465 467
    • (2002) Br. J. Haematol. , vol.116 , pp. 465-467
    • Perrotta, S.1    Locatelli, F.2    La Manna, A.3    Cennamo, L.4    De Stefano, P.5    Nobili, B.6
  • 77
    • 9644274699 scopus 로고    scopus 로고
    • Rituximab in antiphospholipid syndrome
    • J.T. Merrill Rituximab in antiphospholipid syndrome Curr. Rheumatol. Rep. 5 2003 381 382
    • (2003) Curr. Rheumatol. Rep. , vol.5 , pp. 381-382
    • Merrill, J.T.1
  • 78
    • 0033549067 scopus 로고    scopus 로고
    • IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
    • T. Levine, and A. Pestronk IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab Neurology 52 1999 1701 1704
    • (1999) Neurology , vol.52 , pp. 1701-1704
    • Levine, T.1    Pestronk, A.2
  • 80
    • 0242349131 scopus 로고    scopus 로고
    • Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies
    • S. Renaud, M. Gregor, P. Fuhr, D. Lorenz, G. Deuschl, and A. Gratwohl Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies Muscle Nerve 27 2003 611 615
    • (2003) Muscle Nerve , vol.27 , pp. 611-615
    • Renaud, S.1    Gregor, M.2    Fuhr, P.3    Lorenz, D.4    Deuschl, G.5    Gratwohl, A.6
  • 81
    • 0345306732 scopus 로고    scopus 로고
    • Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)
    • M. Narang, J.A. Penner, and D. Williams Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab) Am. J. Hematol. 74 2003 263 267
    • (2003) Am. J. Hematol. , vol.74 , pp. 263-267
    • Narang, M.1    Penner, J.A.2    Williams, D.3
  • 82
    • 0035883071 scopus 로고    scopus 로고
    • Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
    • R. Stasi, A. Pagano, E. Stipa, and S. Amadori Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 2001 952 957
    • (2001) Blood , vol.98 , pp. 952-957
    • Stasi, R.1    Pagano, A.2    Stipa, E.3    Amadori, S.4
  • 83
    • 0037093086 scopus 로고    scopus 로고
    • Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura
    • R. Stasi, E. Stipa, V. Forte, P. Meo, and S. Amadori Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura Blood 99 2002 3872 3873
    • (2002) Blood , vol.99 , pp. 3872-3873
    • Stasi, R.1    Stipa, E.2    Forte, V.3    Meo, P.4    Amadori, S.5
  • 84
    • 0036699047 scopus 로고    scopus 로고
    • Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study
    • A.A. Giagounidis, J. Anhuf, P. Schneider, U. Germing, D. Sohngen, and K. Quabeck Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study Eur. J. Haematol. 69 2002 95 100
    • (2002) Eur. J. Haematol. , vol.69 , pp. 95-100
    • Giagounidis, A.A.1    Anhuf, J.2    Schneider, P.3    Germing, U.4    Sohngen, D.5    Quabeck, K.6
  • 85
    • 0035059346 scopus 로고    scopus 로고
    • Refractory autoimmune thrombocytopenic purpura treatment with Rituximab
    • K. Patel, J. Berman, A. Ferber, and J. Caro Refractory autoimmune thrombocytopenic purpura treatment with Rituximab Am. J. Hematol. 67 2001 59 60
    • (2001) Am. J. Hematol. , vol.67 , pp. 59-60
    • Patel, K.1    Berman, J.2    Ferber, A.3    Caro, J.4
  • 86
    • 0036046116 scopus 로고    scopus 로고
    • Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome
    • B.T. Heelan, V. Tormey, P. Amlot, E. Payne, A. Mehta, and A.D. Webster Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome Br. J. Haematol. 118 2002 1078 1081
    • (2002) Br. J. Haematol. , vol.118 , pp. 1078-1081
    • Heelan, B.T.1    Tormey, V.2    Amlot, P.3    Payne, E.4    Mehta, A.5    Webster, A.D.6
  • 88
    • 0141926665 scopus 로고    scopus 로고
    • Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab
    • N.G. Gottardo, D.L. Baker, and F.R. Willis Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab Pediatr. Hematol. Oncol. 20 2003 557 561
    • (2003) Pediatr. Hematol. Oncol. , vol.20 , pp. 557-561
    • Gottardo, N.G.1    Baker, D.L.2    Willis, F.R.3
  • 89
    • 0037926853 scopus 로고    scopus 로고
    • Rituximab for the treatment of refractory autoimmune hemolytic anemia in children
    • M. Zecca, B. Nobili, U. Ramenghi, S. Perrotta, G. Amendola, and P. Rosito Rituximab for the treatment of refractory autoimmune hemolytic anemia in children Blood 101 2003 3857 3861
    • (2003) Blood , vol.101 , pp. 3857-3861
    • Zecca, M.1    Nobili, B.2    Ramenghi, U.3    Perrotta, S.4    Amendola, G.5    Rosito, P.6
  • 90
    • 0242318191 scopus 로고    scopus 로고
    • Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome
    • T.D. Shanafelt, H.L. Madueme, R.C. Wolf, and A. Tefferi Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome Mayo Clin. Proc. 78 2003 1340 1346
    • (2003) Mayo Clin. Proc. , vol.78 , pp. 1340-1346
    • Shanafelt, T.D.1    Madueme, H.L.2    Wolf, R.C.3    Tefferi, A.4
  • 91
    • 0036196738 scopus 로고    scopus 로고
    • B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87:189-95. Erratum in
    • F. Zaja, I. Iacona, P. Masolini, D. Russo, A. Sperotto, and S. Prosdocimo B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87:189-95. Erratum in Haematologica 87 2002 336
    • (2002) Haematologica , vol.87 , pp. 336
    • Zaja, F.1    Iacona, I.2    Masolini, P.3    Russo, D.4    Sperotto, A.5    Prosdocimo, S.6
  • 92
    • 0036565876 scopus 로고    scopus 로고
    • Mixed warm and cold autoimmune hemolytic anemia: Complete recovery after 2 courses of rituximab treatment
    • M. Morselli, M. Luppi, L. Potenza, S. Tonelli, D. Dini, and G. Leonardi Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment Blood 99 2002 3478 3479
    • (2002) Blood , vol.99 , pp. 3478-3479
    • Morselli, M.1    Luppi, M.2    Potenza, L.3    Tonelli, S.4    Dini, D.5    Leonardi, G.6
  • 93
    • 0036721379 scopus 로고    scopus 로고
    • Severe cold hemagglutinin disease (CHD) successfully treated with rituximab
    • M. Engelhardt, A. Jakob, B. Ruter, M. Trepel, F. Hirsch, and M. Lubbert Severe cold hemagglutinin disease (CHD) successfully treated with rituximab Blood 100 2002 1922 1923
    • (2002) Blood , vol.100 , pp. 1922-1923
    • Engelhardt, M.1    Jakob, A.2    Ruter, B.3    Trepel, M.4    Hirsch, F.5    Lubbert, M.6
  • 94
    • 0034783228 scopus 로고    scopus 로고
    • Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease
    • S. Berentsen, G.E. Tjonnfjord, R. Brudevold, B.T. Gjertsen, R. Langholm, and E. Lokkevik Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease Br. J. Haematol. 115 2001 79 83
    • (2001) Br. J. Haematol. , vol.115 , pp. 79-83
    • Berentsen, S.1    Tjonnfjord, G.E.2    Brudevold, R.3    Gjertsen, B.T.4    Langholm, R.5    Lokkevik, E.6
  • 95
    • 0036283874 scopus 로고    scopus 로고
    • Treatment of primary chronic cold agglutinin disease with rituximab: Maintenance therapy may improve the results
    • M. Pulik, P. Genet, F. Lionnet, and T. Touahri Treatment of primary chronic cold agglutinin disease with rituximab: maintenance therapy may improve the results Br. J. Haematol. 117 2002 998 999
    • (2002) Br. J. Haematol. , vol.117 , pp. 998-999
    • Pulik, M.1    Genet, P.2    Lionnet, F.3    Touahri, T.4
  • 96
    • 0037946760 scopus 로고    scopus 로고
    • Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders
    • G. Trape, L. Fianchi, M. Lai, L. Laurenti, R. Piscitelli, and G. Leone Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders Haematologica 88 2003 223 225
    • (2003) Haematologica , vol.88 , pp. 223-225
    • Trape, G.1    Fianchi, L.2    Lai, M.3    Laurenti, L.4    Piscitelli, R.5    Leone, G.6
  • 97
    • 0037458230 scopus 로고    scopus 로고
    • Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138:105-8. Summary for patients in
    • X. Zheng, A.M. Pallera, L.T. Goodnough, J.E. Sadler, and M.A. Blinder Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138:105-8. Summary for patients in Ann. Intern. Med. 138 2003 I38
    • (2003) Ann. Intern. Med. , vol.138 , pp. 38
    • Zheng, X.1    Pallera, A.M.2    Goodnough, L.T.3    Sadler, J.E.4    Blinder, M.A.5
  • 99
    • 18744410921 scopus 로고    scopus 로고
    • Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab)
    • S. Kain, T.S. Copeland, and M.F. Leahy Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab) Br. J. Haematol. 119 2002 578
    • (2002) Br. J. Haematol. , vol.119 , pp. 578
    • Kain, S.1    Copeland, T.S.2    Leahy, M.F.3
  • 100
    • 0038651237 scopus 로고    scopus 로고
    • American College of Rheumatology ad hoc Committee on Immunologic Testing Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma
    • B.G. Somer, D.E. Tsai, L. Downs, B. Weinstein, and S.J. Schuster American College of Rheumatology ad hoc Committee on Immunologic Testing Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma Arthritis Rheum. 49 2003 394 398
    • (2003) Arthritis Rheum. , vol.49 , pp. 394-398
    • Somer, B.G.1    Tsai, D.E.2    Downs, L.3    Weinstein, B.4    Schuster, S.J.5
  • 101
    • 0036147619 scopus 로고    scopus 로고
    • F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: Before and after anti-CD20 antibody rituximab therapy
    • W.J. Shih, N. Ghesani, Z. Hongming, A. Alavi, S. Schusper, and D. Mozley F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy Clin. Nucl. Med. 27 2002 142 143
    • (2002) Clin. Nucl. Med. , vol.27 , pp. 142-143
    • Shih, W.J.1    Ghesani, N.2    Hongming, Z.3    Alavi, A.4    Schusper, S.5    Mozley, D.6
  • 102
    • 0035674612 scopus 로고    scopus 로고
    • Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy
    • U. Specks, F.C. Fervenza, T.J. Mcdonald, and M.C. Hogan Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy Arthritis Rheum. 44 2001 2836 2840
    • (2001) Arthritis Rheum. , vol.44 , pp. 2836-2840
    • Specks, U.1    Fervenza, F.C.2    McDonald, T.J.3    Hogan, M.C.4
  • 103
    • 0036785195 scopus 로고    scopus 로고
    • Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)
    • K. Arzoo, S. Sadeghi, and H.A. Liebman Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) Ann. Rheum. Dis. 61 2002 922 924
    • (2002) Ann. Rheum. Dis. , vol.61 , pp. 922-924
    • Arzoo, K.1    Sadeghi, S.2    Liebman, H.A.3
  • 106
    • 0037707715 scopus 로고    scopus 로고
    • Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)
    • H.L. Cooper, E. Healy, J.M. Theaker, and P.S. Friedmann Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab) Clin. Exp. Dermatol. 28 2003 366 368
    • (2003) Clin. Exp. Dermatol. , vol.28 , pp. 366-368
    • Cooper, H.L.1    Healy, E.2    Theaker, J.M.3    Friedmann, P.S.4
  • 107
    • 9144262314 scopus 로고    scopus 로고
    • Treatment of refractory pemphigus vulgaris with rituximab (anti-CD 20 monoclonal antibody)
    • A. Dupuy, M. Viguier, C. Bedane, F. Cordoliani, S. Blaise, and F. Aucouturier Treatment of refractory pemphigus vulgaris with rituximab (anti-CD 20 monoclonal antibody) Arch. Dermatol. 140 2004 91 96
    • (2004) Arch. Dermatol. , vol.140 , pp. 91-96
    • Dupuy, A.1    Viguier, M.2    Bedane, C.3    Cordoliani, F.4    Blaise, S.5    Aucouturier, F.6
  • 108
    • 0344874207 scopus 로고    scopus 로고
    • Successful treatment of refractory myasthenia gravis using rituximab: A pediatric case report
    • M.E. Wylam, P.M. Anderson, N.L. Kuntz, and V. Rodriguez Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report J. Pediatr. 143 2003 674 677
    • (2003) J. Pediatr. , vol.143 , pp. 674-677
    • Wylam, M.E.1    Anderson, P.M.2    Kuntz, N.L.3    Rodriguez, V.4
  • 109
    • 0037926826 scopus 로고    scopus 로고
    • Efficacy and safety of rituximab in type II mixed cryoglobulinemia
    • F. Zaja, S. De Vita, C. Mazzaro, S. Sacco, D. Damiani, and G. De Marchi Efficacy and safety of rituximab in type II mixed cryoglobulinemia Blood 101 2003 3827 3834
    • (2003) Blood , vol.101 , pp. 3827-3834
    • Zaja, F.1    De Vita, S.2    Mazzaro, C.3    Sacco, S.4    Damiani, D.5    De Marchi, G.6
  • 110
    • 0038603204 scopus 로고    scopus 로고
    • Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20
    • D. Sansonno, V. De Re, G. Lauletta, F. Tucci, M. Boiocchi, and F. Dammacco Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20 Blood 101 2003 3818 3826
    • (2003) Blood , vol.101 , pp. 3818-3826
    • Sansonno, D.1    De Re, V.2    Lauletta, G.3    Tucci, F.4    Boiocchi, M.5    Dammacco, F.6
  • 113
    • 0037105369 scopus 로고    scopus 로고
    • Rituximab treatment results in impaired secondary humoral immune responsiveness
    • L.E. Van der Kolk, J.W. Baars, M.H. Prins, and M.H. Van Oers Rituximab treatment results in impaired secondary humoral immune responsiveness Blood 100 2002 2257 2259
    • (2002) Blood , vol.100 , pp. 2257-2259
    • Van Der Kolk, L.E.1    Baars, J.W.2    Prins, M.H.3    Van Oers, M.H.4
  • 114
    • 0034254321 scopus 로고    scopus 로고
    • Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab
    • V.R. Sharma, D.R. Fleming, and S.P. Slone Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab Blood 96 2000 1184 1186
    • (2000) Blood , vol.96 , pp. 1184-1186
    • Sharma, V.R.1    Fleming, D.R.2    Slone, S.P.3
  • 115
    • 0035804282 scopus 로고    scopus 로고
    • Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab
    • I. Dervite, D. Hober, and P. Morel Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab N. Engl. J. Med. 344 2001 68 69
    • (2001) N. Engl. J. Med. , vol.344 , pp. 68-69
    • Dervite, I.1    Hober, D.2    Morel, P.3
  • 117
    • 0038309769 scopus 로고    scopus 로고
    • Neutropenia in patients treated with rituximab
    • E. Voog, F. Morschhauser, and P. Solal-Celigny Neutropenia in patients treated with rituximab N. Engl. J. Med. 348 2003 2691 2694 Discussion 2691-4
    • (2003) N. Engl. J. Med. , vol.348 , pp. 2691-2694
    • Voog, E.1    Morschhauser, F.2    Solal-Celigny, P.3
  • 118
    • 0037402501 scopus 로고    scopus 로고
    • Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder
    • E. Jourdan, D. Topart, B. Richard, J. Jourdan, and A. Sotto Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder Leuk. Lymphoma 44 2003 889 890
    • (2003) Leuk. Lymphoma , vol.44 , pp. 889-890
    • Jourdan, E.1    Topart, D.2    Richard, B.3    Jourdan, J.4    Sotto, A.5
  • 119
    • 0036721023 scopus 로고    scopus 로고
    • Glucocorticoids and rituximab in vitro: Synergistic direct antiproliferative and apoptotic effects
    • A.L. Rose, B.E. Smith, and D.G. Maloney Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects Blood 100 2002 1765 1773
    • (2002) Blood , vol.100 , pp. 1765-1773
    • Rose, A.L.1    Smith, B.E.2    Maloney, D.G.3
  • 122
    • 0038309767 scopus 로고    scopus 로고
    • Interstitial pneumonitis related to rituximab therapy
    • C. Burton, R. Kaczmarski, and R. Jan-Mohamed Interstitial pneumonitis related to rituximab therapy N Engl J Med 348 2003 2690 2691 discussion 2690-1
    • (2003) N Engl J Med , vol.348 , pp. 2690-2691
    • Burton, C.1    Kaczmarski, R.2    Jan-Mohamed, R.3
  • 123
    • 0742306799 scopus 로고    scopus 로고
    • Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab
    • E.M. Buda-Okreglak, J.J. Drabick, and N.R. Delaney Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab Ann. Hematol. 83 2004 117 119
    • (2004) Ann. Hematol. , vol.83 , pp. 117-119
    • Buda-Okreglak, E.M.1    Drabick, J.J.2    Delaney, N.R.3
  • 124
    • 0033214207 scopus 로고    scopus 로고
    • Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
    • U. Winkler, M. Jensen, O. Manzke, H. Schulz, V. Diehl, and A. Engert Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) Blood 94 1999 2217 2224
    • (1999) Blood , vol.94 , pp. 2217-2224
    • Winkler, U.1    Jensen, M.2    Manzke, O.3    Schulz, H.4    Diehl, V.5    Engert, A.6
  • 125
    • 20344362960 scopus 로고    scopus 로고
    • Absence of efficacy of infliximab in the trial of Remicade in primary Sjögren's syndrome (TRIPSS): Randomized controlled trial
    • X. Mariette, P. Ravaud, S. Steinfeld, G. Baron, J. Goetz, and E. Hachulla Absence of efficacy of infliximab in the trial of Remicade in primary Sjögren's syndrome (TRIPSS): randomized controlled trial Arthritis Rheum. 2004 (in press)
    • (2004) Arthritis Rheum.
    • Mariette, X.1    Ravaud, P.2    Steinfeld, S.3    Baron, G.4    Goetz, J.5    Hachulla, E.6
  • 126
    • 12444270688 scopus 로고    scopus 로고
    • Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties
    • J. Carnahan, P. Wang, R. Kendall, C. Chen, S. Hu, and T. Boone Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clin. Cancer Res. 9 2003 3982S 3990S
    • (2003) Clin. Cancer Res. , vol.9
    • Carnahan, J.1    Wang, P.2    Kendall, R.3    Chen, C.4    Hu, S.5    Boone, T.6
  • 127
    • 0038724252 scopus 로고    scopus 로고
    • Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    • S. Faderl, D.A. Thomas, S. O'Brien, G. Garcia-Manero, H.M. Kantarjian, and F.J. Giles Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies Blood 101 2003 3413 3415
    • (2003) Blood , vol.101 , pp. 3413-3415
    • Faderl, S.1    Thomas, D.A.2    O'Brien, S.3    Garcia-Manero, G.4    Kantarjian, H.M.5    Giles, F.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.